Pharmacokinetics and Safety of XAV-19, a Swine Glyco-humanized Polyclonal Anti-SARS-CoV-2 Antibody, for COVID-19-Related Moderate Pneumonia: a Randomized, Double-Blind, Placebo-Controlled, Phase IIa Study
Benjamin Gaborit
(1)
,
Eric Dailly
(1)
,
Bernard Vanhove
(2)
,
Régis Josien
(1)
,
Karine Lacombe
(3)
,
Vincent Dubee
(4)
,
Virginie Ferre
(1)
,
Sophie Brouard
(1)
,
Florence Ader
(5)
,
Marie-Anne Vibet
(1)
,
Aurélie Le Thuaut
(1)
,
Richard Danger
,
Laurent Flet
(1)
,
Anne Omnes
(1)
,
Laetitia Berly
(1)
,
Anne Chiffoleau
(1)
,
Alexandra Jobert
(1, 6)
,
Odile Duvaux
,
François Raffi
(1)
1
CHU Nantes -
Centre Hospitalier Universitaire de Nantes
2 Xenothera [Nantes, France]
3 iPLESP - Institut Pierre Louis d'Epidémiologie et de Santé Publique
4 CHU Angers - Centre Hospitalier Universitaire d'Angers
5 HCL - Hospices Civils de Lyon
6 SPHERE - MethodS in Patients-centered outcomes and HEalth ResEarch
2 Xenothera [Nantes, France]
3 iPLESP - Institut Pierre Louis d'Epidémiologie et de Santé Publique
4 CHU Angers - Centre Hospitalier Universitaire d'Angers
5 HCL - Hospices Civils de Lyon
6 SPHERE - MethodS in Patients-centered outcomes and HEalth ResEarch
Benjamin Gaborit
- Fonction : Auteur
- PersonId : 799507
- ORCID : 0000-0002-6076-9722
Karine Lacombe
- Fonction : Auteur
- PersonId : 761537
- ORCID : 0000-0001-8772-9029
- IdRef : 111113245
Vincent Dubee
- Fonction : Auteur
- PersonId : 749534
- IdHAL : vincentdubee
- ORCID : 0000-0002-9982-4741
- IdRef : 183386337
Richard Danger
- Fonction : Auteur
- PersonId : 767374
- ORCID : 0000-0002-5058-795X
- IdRef : 158591453
Alexandra Jobert
- Fonction : Auteur
- PersonId : 746358
- IdHAL : jobert-alexandra
- ORCID : 0000-0001-9117-0934
Odile Duvaux
- Fonction : Auteur
Résumé
We assessed the pharmacokinetics and safety of XAV-19, a swine glyco-humanized polyclonal antibody against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in coronavirus disease 2019 (COVID-19)-related moderate pneumonia. The objective was to evaluate the optimal dose and safety of XAV-19 during this first administration to patients with COVID-19-related moderate pneumonia.